1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,023 | 0,044 | 13:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity | 287 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.05. | Genflow Biosciences - Exercise of Warrants and Issue of Equity | 2 | RNS | ||
| 30.04. | Genflow Biosciences PLC Announces Final Results | 155 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Genflow Biosciences - Final Results | 4 | RNS | ||
| 28.04. | Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements | 171 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 28.04. | Genflow Biosciences - Expansion of Confidentiality Agreements | 1 | RNS | ||
| 20.04. | Genflow kooperiert mit Acuitas bei Technologie zur Verabreichung von Gentherapien | 1 | Investing.com Deutsch | ||
| 20.04. | Genflow partners with Acuitas for gene therapy delivery tech | 2 | Investing.com | ||
| 20.04. | Genflow Biosciences PLC Announces Strategic Technology Collaboration | 258 | ACCESS Newswire | Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April... ► Artikel lesen | |
| 20.04. | Genflow Biosciences - Strategic Technology Collaboration | - | RNS | ||
| 13.04. | Genflow expands patent coverage to muscular disease treatments | 4 | Investing.com | ||
| 13.04. | Genflow Biosciences PLC Announces International Patent Publication | 288 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 13.04. | Genflow Biosciences - International Patent Publication | 2 | RNS | ||
| 08.04. | Genflow reports sustained safety in aged dog gene therapy trial | 3 | Investing.com | ||
| 08.04. | Genflow Biosciences - Update on the Dog Study | - | RNS | ||
| 31.03. | Genflow Biosciences PLC Announces Total Voting Rights | 221 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / March 31, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March... ► Artikel lesen | |
| 31.03. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 05.03. | Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications | 269 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.03. | Genflow Biosciences - Issue of Equity & PDMR Notifications | 3 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Result of GM | 259 | ACCESS Newswire | Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company... ► Artikel lesen |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,026 | -17,61 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,825 | +2,05 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| CO.DON | 0,014 | -20,59 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,100 | +1,85 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| TME PHARMA | 0,082 | -2,84 % | TME Pharma NV: TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS | ||
| DENALI THERAPEUTICS | 15,260 | -8,10 % | Biogen And Denali Stop BIIB122 Development After Phase 2b Parkinson's Trial Shows No Benefit | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and Denali Therapeutics Inc. (DNLI) reported results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), a small molecule inhibitor of LRRK2 in early-stage... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,071 | 0,00 % | Replenish Nutrients Holding GAAP EPS of -$0.03, revenue of $2.96M | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,124 | -1,26 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.05.2026 | Das Instrument POH3 US14365C1036 CARNIVAL PLC ADR/1 DL1,66 EQUITY wird cum Kapitalmassnahme gehandelt am 06.05.2026 und ex Kapitalmassnahme am 07.05.2026 The instrument POH3 US14365C1036 CARNIVAL PLC... ► Artikel lesen | |
| BIOAGE LABS | 14,300 | -0,76 % | BioAge Labs, Inc.: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,044 | -100,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen | |
| NANOSPHERE HEALTH SCIENCES | 0,002 | 0,00 % | Nanosphere Health Sciences Inc (2): Nanosphere Health adopts semi-annual reporting | ||
| TELO GENOMICS | 0,033 | -8,33 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,023 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.